Codexis (CDXS) announced its first revenue-generating contract to manufacture siRNA material in its ECO Synthesis Innovation Lab. Codexis has also successfully completed development of the first generation of its core ECO Synthesis enzymes, having met the pre-specified criteria to support scaling to industrial capacity.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXS: